IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David R. Scholl et al.

Serial No.: 10/578,146 Art Unit: 1648

Filed: 05/03/2006 Examiner: Blumel, B.P. Entitled: Compositions And Methods For Detecting Severe Acute Respiratory

Syndrome Coronavirus

DECLARATION OF DR. JOESPH D. JOLLICK UNDER 37 CFR § 1.132

Mail Stop –Amendment Commissioner for Patents P.O. Box 1450 Alexandria. VA 22313-1450

Examiner Blumel:

- I, Dr. Joesph D. Jollick, under penalty of perjury, state that:
 - I am the a co-inventor of the embodiments of the invention as claimed in the United States patent application captioned above.
 - I am an expert in the field of virology and was an employee of Diagnostics
 Hybrids, Inc.
 - 3. The attached data demonstrates that a composition termed SARS Arrest comprising 32 µg/ml E64D did not inhibit the replication of the same 'not a plus-RNA strand' viruses as listed in Table 5 of the above captioned patent application. See, Exhibit A.
 - The attached data demonstrates that E64D completely inhibits coronavirus replication between 2 - 32 μg/ml. See, Exhibit B.

5. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing therefrom.

Dated: May 3, 2010




Exhibit A

E64d concentration (ug/ml)	32	16	8	4	2	1	0.5	0.25	0
	0	0	0	0	0	2	17	36	45
E64d	0	0	0	0	0	1	3	20	54
Average	0	0	()	0	0	1.5	10	28	49.5
Percent Replication	0%	0%	0%	0%	0%	3%	20%	57%	100%

Exhibit B